Last updated: July 19, 2026
ecutive summary
Allergan, Inc. v. Somerset Therapeutics, LLC (D. Del. C.A. No. 1:16-cv-00392) is a federal Hatch-Waxman patent infringement action tied to generic competition for an Allergan product. The docket reflects an Android “Orange Book” style dispute under 35 U.S.C. § 271(e)(2), but the provided record excerpt does not include the asserted patents, claim construction, claim chart provisions, dispositive motion outcomes, or the case-ending date and judgment. Without those items, a complete, citation-grade litigation summary and legal analysis cannot be produced.
Litigation summary and analysis for Allergan, Inc. v. Somerset Therapeutics, LLC|1:16-cv-00392
What happened in Allergan v. Somerset Therapeutics in 1:16-cv-00392?
A complete litigation summary requires the asserted patent list, the generic product identity, the procedural posture at key milestones (complaint, answer, early motions, Markman/claim construction, summary judgment), and the disposition (settlement, dismissal, final judgment). Those details are not present in the information provided here, so no accurate event-by-event recap can be generated.
What patents were asserted in the complaint?
The case outcome and infringement scope depend on the specific Orange Book patents listed in Allergan’s infringement pleading, including whether the asserted claims cover:
- composition/formulation (drug substance, dosage form, or manufacturing-related features),
- method-of-use,
- and/or device or combination features (if applicable).
No asserted-patent numbers or titles are included in the provided input, so the patent estate being litigated cannot be identified.
What generic ANDA was at issue?
Litigation under § 271(e)(2) turns on the ANDA submission and the Paragraph IV certification(s). A correct summary must identify:
- ANDA number,
- filing date (or amendment chronology),
- certification type (I-IV) and the specific paragraphs triggering the suit,
- and the proposed labeling.
Those items are not included in the provided input.
Why did Allergan sue Somerset under Hatch-Waxman at D. Del. 1:16-cv-00392?
A valid “why” analysis ties the suit to the exclusivity landscape and the specific carve-out(s) claimed by the generic filer.
What Paragraph IV trigger drove the litigation?
A § 271(e)(2) case is triggered by an ANDA certification to a listed Orange Book patent that the generic applicant challenges as invalid, unenforceable, or not infringed. Without the patent list and the certification record, the trigger cannot be stated accurately.
What exclusivity or Orange Book listings were in play?
For business and litigation analysis, exclusivity typically includes:
- listed patents for the branded drug,
- regulatory exclusivities (NCE, 3-year, 5-year, pediatric),
- and any terminal disclaimers affecting expiration.
The provided input contains none of the Orange Book listing details needed to connect the litigation to the exclusivity timetable.
What was the procedural timeline in Allergan v. Somerset (1:16-cv-00392)?
A timeline for litigation analysis needs dates for:
- complaint filing,
- service and answer,
- early motion practice (Rule 12, venue or pleadings),
- claim construction (Markman) schedule,
- summary judgment or dispositive rulings,
- trial (if any),
- and final disposition (settlement/dismissal/judgment).
No docket date sequence or order list is available in the provided input, so the timeline cannot be reconstructed accurately.
Did the court issue claim construction, and how did it affect infringement?
To analyze strength and predict settlement or appeal posture, claim construction outcomes matter. A correct analysis would cite:
- the asserted claim language,
- the construed meanings,
- and how those constructions map to the generic formulation and use.
No claim construction record or claim terms are included in the provided input.
How strong were Allergan’s infringement and validity positions?
Patent strength analysis typically requires:
- how the court treated infringement theories (literal vs doctrine of equivalents),
- validity arguments (anticipation, obviousness, enablement, written description, indefiniteness, obviousness-type double patenting),
- and any evidence rulings (expert exclusion, priority, inherency).
The provided input does not include any opinions, summary judgment rulings, or trial outcomes, so strength cannot be evaluated.
What was the settlement or dismissal posture in 1:16-cv-00392?
Many Hatch-Waxman cases resolve via settlement or dismissal after negotiated terms tied to:
- launch date carve-outs,
- payment structure (reverse payments if applicable),
- supply and exclusivity covenants,
- and scope constraints in the license.
The provided input includes no settlement agreement terms, dismissal notice, or final judgment entry, so this cannot be summarized without fabricating facts.
What generic entry risks did the case present for Somerset?
Generic entry risk depends on:
- whether the case ended in an adjudication of infringement/validity,
- whether any appeal stayed launch,
- and whether a settlement permitted a limited “at-risk” entry date.
No dispositive outcome is provided, so the launch-risk analysis cannot be completed.
How does this case compare with other Allergan v. generic challengers in Hatch-Waxman?
Comparison requires the asserted patent set, product type, and litigation outcome across similar Allergan cases (for example, whether Allergan won on validity, reached early settlement, or lost claim construction). None of those comparative anchor points are available in the provided input.
Key Takeaways
- A precise litigation summary and legal analysis for Allergan, Inc. v. Somerset Therapeutics, LLC (1:16-cv-00392) requires docket-verified facts including the asserted patents, ANDA/patent certifications, procedural milestones, and disposition.
- The provided input does not include the necessary case record elements to produce an accurate, complete analysis.
FAQs
- What patents does Allergan assert in 1:16-cv-00392?
- Which ANDA and Paragraph IV certification triggered the infringement claims in this case?
- Did the court construe any claims in 1:16-cv-00392, and what terms were pivotal?
- Was the matter dismissed or resolved by settlement, and what were the practical launch implications?
- Does 1:16-cv-00392 align with Allergan’s typical strategy in Hatch-Waxman disputes, and how?
References
- (No sources were provided in the input.)
